Dianthus Therapeutics (DNTH) Earnings Analysis

Dianthus Therapeutics (DNTH) next reports earnings on 2026-08-06, consensus EPS -0.84628 USD. Last quarter (2026-03-09) it missed with EPS -1.43 USD vs -0.98 USD est (-45.9%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -934.18.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does DNTH next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.84628 USD
Revenue estimate0.00B

DNTH earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-09-1.43 USD-0.98 USD-45.9%Miss
2025-08-07-0.88 USD-0.86 USD-2.3%Miss
2025-05-12-0.82 USD-0.86 USD+4.7%Beat
2025-03-11-0.81 USD-0.85 USD+4.7%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

DNTH valuation and analyst view

Trailing P/E-934.18
Trailing EPS-0.23574 USD
Price / book4.11
Dividend yield0.00%
Market cap4.36B
Analyst consensusBuy (10 buy / 0 hold / 0 sell)
Avg price target125.67 USD

Related research pages

Frequently asked questions

When is Dianthus Therapeutics (DNTH)'s next earnings date?

Dianthus Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.84628 USD and revenue estimate of 0.00B.

Did DNTH beat earnings last quarter?

In its 2026-03-09 report, DNTH posted EPS of -1.43 USD versus a -0.98 USD estimate — a miss of 45.9%.

What is DNTH's earnings track record?

Over the last 4 reported quarters with consensus data, DNTH beat estimates 2 times (50%).

What is DNTH's current P/E ratio and EPS?

DNTH trades at a trailing P/E of -934.18 on trailing EPS of -0.23573503257423864 USD.

What do analysts rate DNTH?

Analyst consensus is "Buy" across 10 ratings (1 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 125.67 USD.